Leonie Uhl

Leonie Uhl

Auto-generated profile, based on publicly available information

Leonie Uhl

Theodor Boveri Institute, Department of Biochemistry and Molecular Biology, Biocenter, University of Würzburg; Am Hubland, 97074 Würzburg, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in Nature
Verified
Journal Article
Closed access
PDF file
DSDaniel Solvie
Daniel Solvie
ABApoorva Baluapuri
Apoorva Baluapuri
LULeonie Uhl
Leonie Uhl
DFDaniel Fleischhauer
Daniel Fleischhauer
TETheresa Endres
Theresa Endres
MEMartin Eilers
Martin Eilers

25 September 2023 in Nature Cancer
Verified
Journal Article
Open access
PDF file
JTJacqueline Taylor
Jacqueline Taylor
LULeonie Uhl
Leonie Uhl
IMIris Moll
Iris Moll
SHSana Safatul Hasan
Sana Safatul Hasan
LWLena Wiedmann
Lena Wiedmann
AFAndreas Fischer
Andreas Fischer
Cachexia is a major cause of morbidity and mortality in individuals with cancer and is characterized by weight loss due to adipose and muscle tissue wasting. Hallmarks of white adipose tissue (WAT) remodeling, which often precedes weight loss, are impaired lipid storage, inflammation and eventually fibrosis. Tissue wasting occurs in response to tumor-secreted factors. Considering that the continuous endothelium in WAT is the first line of contact with circulating factors, we postulated whether the endothelium itself may orchestrate tissue remodeling. Here, we show using human and mouse cancer models that during precachexia, tumors overactivate Notch1 signaling in distant WAT endothelium. Sustained endothelial Notch1 signaling induces a WAT wasting phenotype in male mice through excessive retinoic acid production. Pharmacological blockade of retinoic acid signaling was sufficient to inhibit WAT wasting in a mouse cancer cachexia model. This demonstrates that cancer manipulates the endothelium at distant sites to mediate WAT wasting by altering angiocrine signals.

19 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MMMareike Müller
Mareike Müller
LELorenz Eing
Lorenz Eing
LULeonie Uhl
Leonie Uhl
MSMaximilian Schmitz
Maximilian Schmitz
IKIliyana Kaneva
Iliyana Kaneva
GBGabriele Büchel
Gabriele Büchel
Summary: Deregulated MYCN is a driver of aggressive pediatric and adult neuroendocrine tumors, but critical oncogenic processes downstream of MYCN remain poorly defined. In neuroblastoma, MYCN interacts with and activates the Aurora-A kinase. Here we show that Aurora-A is a CDK-activating kinase for CDK12 by phosphorylating T893 in the T-loop, thereby enhancing its kinase activity. Aurora-A-dependent activation of CDK12 controls phosphorylation of T4 of RNA polymerase and recruits transcription termination complexes, thereby preventing transcription-replication conflicts. Enhanced crosslinking and immunoprecipitation sequencing reveals that Aurora-A associates with splice sites on nascent RNA. RNA-bound Aurora-A is catalytically inactive. MYCN competes with RNA for binding to Aurora-A and displaces Aurora-A from RNA in cells, promoting its CDK12 kinase activity. Combining Aurora-A and CDK12 inhibition potently suppresses the growth of MYCN -amplified neuroblastoma cells and patient-derived xenografts. Our data demonstrate that an Aurora-A/CDK12-dependent transcription termination pathway is a critical and targetable dependency of MYCN-driven tumors.

6 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
LULeonie Uhl
Leonie Uhl
AAAmel Aziba
Amel Aziba
SLSinah Löbbert
Sinah Löbbert
TRTimothy Russell
Timothy Russell
TKToshitha Kannan
Toshitha Kannan
MEMartin Eilers
Martin Eilers
In response to perturbed transcription elongation, the MYC oncoprotein multimerizes and undergoes a phase transition; the underlying mechanisms and their function are unknown. Here, we show that MYC re-localizes from its canonical location on DNA to RNA in response to the accumulation of intronic RNA. MYC binds RNA directly, which enhances its multimerization. MYC multimers concentrate the nuclear exosome, a 3’-5’ RNA exonuclease, and its targeting complexes around double-stranded RNA and R-loops, and promote exosome recruitment to R-loops. RNA binding of MYC suppresses activation of the innate immune kinase TBK1. Upon MYC depletion, intron-derived dsRNAs, including RNA derived from repetitive elements and small nucleolar RNAs, accumulate on TLR3, a pattern recognition receptor that activates TBK1. In MYC-depleted cells, TLR3-bound snoRNAs carry aberrant 3’-ends, indicating defective exosomal processing. Our data show that the phase transition of MYC is a RNA-driven stress response that suppresses the accumulation of immunogenic RNAs.